EQRx, Inc.

EQRx, Inc., trading under the ticker CMLT, filed an 8-K with the SEC on October 3, 2022, reflecting the biopharmaceutical company's public market activity following its SPAC business combination. The blank-check vehicle, which targeted the healthcare and life sciences sector, completed its initial public offering in 2021. EQRx is focused on developing and commercializing innovative medicines at substantially lower prices than conventional market rates, with programs spanning oncology and immunology. The filing is part of the company's ongoing SEC reporting obligations as a post-merger publicly traded entity. For comprehensive filing timelines, deal analytics, and real-time SPAC data on EQRx and the broader market, sign up for full access at SpacDesk.